Cleo Diagnostics
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 24 Aug 2026
- Reported shorts
- 6.3K
- Shares on issue
- 137.112M
Cleo Diagnostics (COV) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $1.9MM (source: ASX (Markit))vs $1.2MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$5.9Mvs −$4.0M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.045vs −$0.031 (FY25)
- Yahoo Finance, as at 14 Oct 2026
- Rev YoY
- +64.5%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
Summary of Appendix 4E and 2026 Annual Report, 20 Aug 2026
Cleo Diagnostics reported FY2026 revenue of $232,352, down 31.6%, and a net loss of $5,936,480, widening 48.4% from the prior year. No dividend was declared. The company is advancing toward FDA submission for its ovarian cancer test, with analytical validation commencing in H2 CY2026 and a planned 510(k) submission in the first half of CY2027.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −404.5%
- Net margin
- −304.5%
- FCF margin
- −253.8%
- ROE
- −109.5%
- ROA
- −87.2%
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 3.8×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $45.2M
- P/E
- n/a
- P/B
- 9.0×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $1.9MM (source: ASX (Markit)) | $1.2MM (source: ASX (Markit)) | $600.1KM (source: ASX (Markit)) | $110.1KM (source: ASX (Markit)) |
| Operating income | −$7.9M | −$5.2M | −$4.3M | −$1.7M |
| EBITDA | −$7.8M | −$5.1M | −$3.7M | −$1.6M |
| EBIT | −$7.9M | −$5.2M | −$3.7M | −$1.6M |
| Interest expense | n/a | n/a | $26.5K | $110.8K |
| Pretax income | −$5.9M | −$4.0M | −$3.8M | −$1.7M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$5.9M | −$4.0M | −$3.8M | −$1.7M |
| Net interest income | $232.4K | $339.6K | $336.3K | −$110.8K |
| EPS basic | −$0.045 | −$0.031 | −$0.032 | −$0.066 |
| EPS diluted | −$0.045 | −$0.031 | −$0.032 | −$0.066 |
| Shares | 137.1M | 128.5M | 128.5M | 45.0M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results20 Aug 2026via asx_announcements
- Appendix 4D and Half Yearly AccountsHalf Year Results25 Feb 2026via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results26 Aug 2025via asx_announcements
- Appendix 4D and Half Yearly AccountsHalf Year Results27 Feb 2025via asx_announcements
- Appendix 4E and 2024 Annual ReportAnnual Results27 Aug 2024via asx_announcements
- Appendix 4D and Half Yearly AccountsHalf Year Results29 Feb 2024via asx_announcements
- SEE PRESENTATIONFinancial Reportvia crawler